Pharmacyclics pullback makes it attractive, says Brean Capital Brean Capital said the pullback in Pharmacyclics had made it one of the most attractive investment opportunities in its space. The firm cited positive Phase 3 studies for ibrutinib which highlighted its potential as a front line therapy in the next 3-4 years. Shares are Buy rated with an $80 price target.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.